| Title | Review of teriflunomide and its potential in the treatment of multiple sclerosis. | | Author(s) | Warnke C, Meyer Zu Hörste G, Hartung HP, Stüve O, Kieseier BC | | Institution | Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; | | Source | Neuropsychiatr Dis Treat 2009.:333-40. | | Abstract | In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19557143 |
|
